- Home
- RLAY vs GCMG Comparison
RLAY vs GCMG Comparison
Compare RLAY & GCMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- GCMG
- Stock Information
- Founded
- RLAY 2015
- GCMG 1971
- Country
- RLAY United States
- GCMG United States
- Employees
- RLAY N/A
- GCMG N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- GCMG Finance/Investors Services
- Sector
- RLAY Health Care
- GCMG Finance
- Exchange
- RLAY Nasdaq
- GCMG Nasdaq
- Market Cap
- RLAY 619.0M
- GCMG 631.4M
- IPO Year
- RLAY 2020
- GCMG N/A
- Fundamental
- Price
- RLAY $3.99
- GCMG $12.88
- Analyst Decision
- RLAY Strong Buy
- GCMG Buy
- Analyst Count
- RLAY 13
- GCMG 4
- Target Price
- RLAY $18.00
- GCMG $15.13
- AVG Volume (30 Days)
- RLAY 1.2M
- GCMG 457.8K
- Earning Date
- RLAY 11-05-2025
- GCMG 11-07-2025
- Dividend Yield
- RLAY N/A
- GCMG 3.42%
- EPS Growth
- RLAY N/A
- GCMG N/A
- EPS
- RLAY N/A
- GCMG 0.19
- Revenue
- RLAY $8,355,000.00
- GCMG $533,097,999.00
- Revenue This Year
- RLAY $31.55
- GCMG $4.88
- Revenue Next Year
- RLAY N/A
- GCMG $11.78
- P/E Ratio
- RLAY N/A
- GCMG $69.29
- Revenue Growth
- RLAY N/A
- GCMG 15.56
- 52 Week Low
- RLAY $1.78
- GCMG $10.74
- 52 Week High
- RLAY $8.32
- GCMG $14.48
- Technical
- Relative Strength Index (RSI)
- RLAY 58.70
- GCMG 57.85
- Support Level
- RLAY $3.87
- GCMG $12.63
- Resistance Level
- RLAY $4.20
- GCMG $12.98
- Average True Range (ATR)
- RLAY 0.21
- GCMG 0.19
- MACD
- RLAY 0.03
- GCMG -0.04
- Stochastic Oscillator
- RLAY 66.87
- GCMG 62.30
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.